Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
£ 774
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Undervalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as...
Company Valuation
Based on key historical and expected multiples, the stock is undervalued relative to its peers.
Data is available to registered users only
Target Price
The average target price of OXB.L is 746 and suggests 4% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to decr
Data is available to registered users only
Buy
Sell